卡瑞利珠单抗联合mFOLFIRI方案对结肠癌的疗效及其对血管新生指标及恶性细胞增殖活性的影响  

The Effect of Carrelizumab Combined with mFOLFIRI Regimen in the Treatment of Colon Cancer on Angiogenesis Indicators and Malignant Cell Proliferation Activity

作　　者：孟元普[1] 裴哲[1] 周博[1] MENG Yuanpu;PEI Zhe;ZHOU Bo(The First Affiliated Hospital of Henan University of Science and Technology,Luoyang,471000)

机构地区：[1]河南科技大学第一附属医院,471000

出　　处：《实用癌症杂志》2023年第9期1502-1506,共5页The Practical Journal of Cancer

摘　　要：目的探讨卡瑞利珠单抗联合mFOLFIRI方案治疗结肠癌对血管新生指标及恶性细胞增殖活性的影响。方法选取结肠癌患者106例进行前瞻性研究,采用简单随机化法分为观察组(n=53)、对照组(n=53)。对照组采用mFOLFIRI方案治疗,观察组采用卡瑞利珠单抗联合mFOLFIRI方案治疗。比较两组疗效、不良反应、生活质量状况及治疗前后血清肿瘤标志物水平、血管新生指标、恶性细胞增殖活性。结果观察组疾病控制率(88.68%)高于对照组(73.58%)(P<0.05);两组不良反应发生率无显著差异(P>0.05);治疗后观察组血清CEA、CCSA-2、CA199、VEGF、VEGFR-2、Ang-2、PI3K、Akt水平低于对照组(P<0.05);观察组生活质量提高稳定率(83.02%)高于对照组(64.15%)(P<0.05)。结论卡瑞利珠单抗联合mFOLFIRI方案治疗结肠癌效果确切,不良反应可控,利于提高患者生活质量,其机制可能与调节血管生长因子VEGF、VEGFR-2、Ang-2表达及抑制PI3K/Akt通路过度激活有关。Objective To explore the effect of carrelizumab combined with mFOLFIRI regimen in the treatment of colon cancer on angiogenesis indicators and malignant cell proliferation activity.Methods A prospective study was conducted on 106 patients with colon cancer,and they were divided into the observation group(n=53)and the control group(n=53)by simple randomization method.The control group was treated with mFOLFIRI regimen,and the observation group was treated with carrelizumab combined with mFOLFIRI regimen.The efficacy,adverse reactions,quality of life status and serum tumor markers[carcinoembryonic antigen(CEA),colon cancer specific antigen-2(CCSA-2),carbohydrate antigen 199(CA199)],angiogenesis Indicators[vascular endothelial growth factor(VEGF),VEGF receptor-2(VEGFR-2),angiopoietin-2(Ang-2)],malignant cell proliferation activity[serum phosphatidylinositol 3-kinase(PI3K),Serine-threonine protein kinase(Akt)levels]before and after treatment were compared between the 2 groups.Results The disease control rate of the observation group was 88.68%higher than that of the control group 73.58%(P<0.05);There was no significant difference in the incidence of adverse reactions between the 2 groups(P>0.05);After treatment,the serum levels of CEA,CCSA-2,CA199,VEGF,VEGFR-2,Ang-2,PI3K,and Akt in the observation group were lower than those in the control group(P<0.05);The stable rate of quality of life improvement in the observation group was 83.02%higher than that of the control group 64.15%(P<0.05).Conclusion Carrelizumab combined with mFOLFIRI regimen has a definite effect in the treatment of colon cancer,with controllable adverse reactions,which is beneficial to improve the quality of life of patients.Its mechanism may be related to the regulation of the expression of vascular growth factors VEGF,VEGFR-2,Ang-2 and inhibition of PI3K/Akt pathway overactivation is related.

关 键 词：卡瑞利珠单抗 mFOLFIRI方案 结肠癌 血管新生 恶性细胞增殖活性 

分 类 号：R735.3[医药卫生—肿瘤]